Novartis study tries to temper regulatory onslaught in Europe

As European countries line up with ever-stricter rules designed to reduce the price they pay for pharmaceuticals, Novartis has commissioned a new report from a group of tech experts that draws a straight line between the strictness of the new regs and a reduction in R&D innovation. In clear and measured language, the European School of Management and Technology Competition Analysis note that a strict regulatory environment inevitably shifts the attention of drug developers to new therapies...